ERBB2 and breast cancer: A recent meta-analysis of data indicated that compared with ET alone, treatment with CDK4/6 inhibitors plus ET was associated with significantly improved OS, PFS, and objective response rate (ORR) among patients with ER+/HER2− metastatic BC [24].